Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03411837 · ClinicalTrials.gov registry record
Dupilumab Phase 4 Study
A clinical trial, sponsored by Northwestern University.
- Terminated
- Registry status
- 46
- Enrollment target
NCT03411837 is a clinical trial that was terminated before completion, run by Northwestern University. The registered enrollment target is 46 participants.
The verdict
NCT03411837 was terminated before completion, sponsored by Northwestern University.
- TERMINATED
- Registry status
- 46 participants
- Enrollment target
Study Summary
The investigators will monitor for the incidence of adverse-events in a prospective, longitudinal, non-interventional and observational real-world sub-study of adults patients with moderate-to-severe AD who are receiving dupilumab as standard-of-care therapy.
Interventions
- BIOLOGICAL Dupilumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2017-10-16 |
| Est. Completion | 2019-08-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03411837
The ClinicalTrials.gov registry entry for NCT03411837 describes a study currently listed as terminated, categorized as an unspecified phase. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Dupilumab is the first listed.
NCT03411837 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03411837 about?
NCT03411837 is a clinical study titled "Dupilumab Phase 4 Study". The investigators will monitor for the incidence of adverse-events in a prospective, longitudinal, non-interventional and observational real-world sub-study of adults patients with moderate-to-severe AD who are receiving dupilumab as standard-of-care therapy.
What is the current status of trial NCT03411837?
This trial is currently terminated. The enrollment target is 46 participants. The study started on 2017-10-16. Estimated completion is 2019-08-31.
What interventions are being tested in trial NCT03411837?
The interventions under investigation include: Dupilumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT03411837?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.